Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.66 |
| ▸ | CTSL | P07711 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 3/20 | 0.63 |
| ▸ | CTSK | P43235 | 3/20 | 0.63 |
| ▸ | CTSH | P09668 | 1/20 | 0.63 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.61 |
| ▸ | CALCR | P30988 | 1/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544836 | 1.00 | CXCR4 (0.66) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29389088 | 0.98 | CXCR4 (0.65) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29466602 | 0.88 | NMBR (0.62) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30512640 | 0.88 | CXCR4 (0.69) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31183030 | 0.87 | NPY1R (0.67) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29378658 | 0.87 | CXCR4 (0.69) | CXCR4 | |
| SCHEMBL29379177 | 0.86 | KISS1R (0.67) | CXCR4 | |
| SCHEMBL31182897 | 0.86 | CXCR4 (0.71) | CXCR4RAMP3CALCRNPY1RNPY2R | |
| SCHEMBL31011012 | 0.86 | CXCR4 (0.68) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31246283 | 0.86 | GIPR (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11319374-B2 | Inhibitors of prototypic galectin dimerization and uses thereof | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CXCR4 1234/4885CTSL 217/4885CTSS 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.